Home – CDMO Solutions | Viral Vectors | Lentivirus
30 years of lentiviral vector manufacturing
As a pioneer in lentiviral vector technology, OXB brings three decades of proven experience to the development and manufacturing of lentiviral vectors for cell and gene therapies. Now a global CDMO, we support partners from early development through to commercialisation.
With over 340 GMP batches successfully manufactured, and 25 regulatory submissions supported, OXB offers deep regulatory, process, and analytical expertise to accelerate advanced therapy programmes from discovery to market.
OXB’s lentiviral vector track record
0+
GMP batches successfully released
0
Successful regulatory submissions
0
monthsTo GMP release
0E+
12 TUAt 200L scale
0%
Analytical assays performed in-house
0+
Patients’ doses
LentiVector™ platform
Taking novel therapies from discovery to commercialisation
OXB’s LentiVector™ platform offers a fully integrated and optimised suite of technologies and processes for the scalable production of high-quality lentiviral vectors. Designed to meet the complex demands of the cell and gene therapy market, the platform encompasses vector design, upstream and downstream processing, analytics, and fill/finish services, all aligned to deliver robust, reproducible GMP manufacturing.
The platform offers 3rd generation and 4th generation lentiviral vector systems, including proprietary innovations; 2KO genome™, SupA-LTR™, MaxPax™, and the TRiP System™, that together can enhance vector potency, productivity, quality, and safety.
With the LentiVector™ platform, clients benefit from high-yield, high-volume GMP manufacturing, scalable from early clinical to commercial supply, supported by deep regulatory expertise across global markets.
Explore the LentiVector™ platform
Our platform technologies:
Related resources
How to De-risk Preclinical Lentiviral Manufacturing Ahead of IND
Practical guidance for teams translating promising lentiviral vectors into reproducible development programmes
View details >How to Avoid Preclinical Risk by Getting Lentiviral Decisions Right in Discovery
Practical guidance for discovery teams making lentiviral decisions that shape programme success.
View details >Improved Production and Quality of Lentiviral Vectors by Major-Splice-Donor Mutation and Co-expression of a Novel U1 snRNA-based Enhancer
Discover how the TetraVecta™ system eliminates aberrant vector RNA splicing, enhances TRiP system™ performance, and improves the safety and utility of next-generation gene therapy vectors.
View PDF >Enhanced Transcriptional Insulation of Lentiviral Vectors using “Sequence Upgraded polyA Long Terminal Repeats” or “supA-LTRs”
SupA-LTR technology enhances lentiviral vector safety and performance by reducing transcriptional read-through, improving polyadenylation, and increasing transgene expression.
View PDF >Development and Scale Up of Next Generation LV Batch Process Demonstrating Increased Productivity and Enhanced Purity
This poster highlights how a new lentiviral (LV) process improves recovery using next-generation anion exchange chromatography (AIEX). It also presents strategies to achieve approximately a threefold reduction in residual DNA impurities and demonstrates a scalable, GMP-ready platform validated at up to 200 liters.
View PDF >Justifying a Pathway to Reduced Replication-Competent Lentivirus (RCL) Testing: Adding the Empirical to the Theoretical
This presentation focuses on the topic of replication-competent lentiviruses (RCLs), explaining why they have not been observed to date and introducing frameworks for distinguishing between possible and plausible RCL risk. It also outlines future strategies aimed at optimizing and potentially reducing RCL testing requirements.
View PDF >Why choose OXB as your LV CDMO?
Taking novel therapies from discovery to commercialisation
Access innovative technology and unmatched expertise
With decades of leadership in lentiviral vector production, OXB gives clients access to some of the industry’s most experienced scientific minds. Our commitment to continuous innovation ensures clients benefit from the latest advancements in viral vector manufacturing to deliver best in class cell and gene therapies.
Receive comprehensive regulatory support through to commercialisation
OXB provides end-to-end regulatory support, guiding clients from preclinical development through to commercial launch. We have successfully supported multiple IND and MAA submissions, and maintain a Drug Master File (DMF) with the FDA, reinforcing our credibility as a trusted global CDMO partner.
Leverage local manufacturing with a global footprint
With harmonised lentiviral vector manufacturing processes across our UK, US, and European facilities, OXB enables efficient, scalable production from 50L to 1000L, close to your clinical or commercial markets. Our global footprint ensures flexibility, consistency, and speed—wherever you are.
Ways to work with us
There are multiple ways in which pharma, biotechs and start-ups work with us, depending on development phase, scale, and individual IP requirements.
Platform project
For clients that are pre-clinical or early-clinical that wish to reach GMP at an accelerated rate with a proven process.
Custom solution
For clients that are pre-clinical or early-clinical that require flexibility in the manufacture of their drug candidate.
Tech-transfer
For clients in phase I, II, or III that need to transfer their manufacture to a CDMO for scale and/or long-term manufacture.
Frequently asked questions
Yes, OXB has supported clients through every development phase from discovery, pre-clinical, clinical and commercial. We currently manufacture for 2 commercial programmes.
OXB has a suite of over 40 analytical methods, with 90% of these in-house. These include assays for measuring biological activity, identity, purity, quantity and safety.
OXB can tech transfer-in and out for products in any phase of development. We use a phase-appropriate 5 stage methodology designed to be adaptable, meeting the unique requirements of each client at various stages of development. Visit our resources hub to learn more about our tech transfer experience.
OXB has strong experience in supporting clients through commercialisation and currently manufactures for 2 commercial programmes. We have a proven track record in supporting global regulatory filings, including 30+ successful IND submissions and 2 BLA/MAA submissions.
Looking for something specific? – let's discuss a custom project
For pre-clinical clients that would like to co-develop a highly specific process, our custom project offering allows you to access OXB’s technology in combination with others to create a truly unique solution to meet your individual requirements.
